Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
Primary Purpose
Diabetes Mellitus Type 2
Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Glucophage
Glucophage
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2 focused on measuring Diabetes, Glucophage, Metformin, sachets, tablets
Eligibility Criteria
Inclusion Criteria:
- Diabetes mellitus type 2 diagnosed (Baseline Glycemia > 7,0 mmol/L (126 mg/dL) or overload Glycemia > 11,0 mmol/L (198 mg/dL)
- On treatment with metformin tablets
- Patients with at least 2 treated co-morbidities
- Established dose of Metformin > 1.700 mg/day
- Age > 18 years old
- Given informed consent
Exclusion Criteria:
- Patients not able to take medication orally
- According to Summary of Product Characteristics (SmPC)
- Participating in another clinical trial 30 days prior to randomization
- Any other illness or medical or psychiatric condition, severe and uncontrolled that could interfere in the patient's participation or in the assessment of the study results
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Glucophage sachets
Glucophage tablets
Arm Description
Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
Patients received Glucophage tablets.
Outcomes
Primary Outcome Measures
Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6
Secondary Outcome Measures
Objective compliance to treatment
Objective compliance to treatment is assessed by the accountability of medication returned. Patient is assessed as compliant with an adherence of over 80%.
Evaluation of treatment satisfaction and preferences with the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Rate of reported adverse events
Full Information
NCT ID
NCT01510522
First Posted
December 30, 2011
Last Updated
February 3, 2014
Sponsor
Merck KGaA, Darmstadt, Germany
Collaborators
Merck, S.L., Spain
1. Study Identification
Unique Protocol Identification Number
NCT01510522
Brief Title
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
Official Title
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients, Previously Treated With Metformin Tablets
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Withdrawn
Study Start Date
June 2012 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck KGaA, Darmstadt, Germany
Collaborators
Merck, S.L., Spain
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is an open-label, multicenter, two-arm, parallel, randomized phase 4 study to compare the compliance in diabetes type 2 patients treated with Glucophage sachets versus patients treated with Glucophage tablets.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
Keywords
Diabetes, Glucophage, Metformin, sachets, tablets
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Glucophage sachets
Arm Type
Experimental
Arm Description
Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
Arm Title
Glucophage tablets
Arm Type
Active Comparator
Arm Description
Patients received Glucophage tablets.
Intervention Type
Drug
Intervention Name(s)
Glucophage
Other Intervention Name(s)
Metformin hydrochloride
Intervention Description
Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
Intervention Type
Drug
Intervention Name(s)
Glucophage
Other Intervention Name(s)
Metformin hydrochloride
Intervention Description
Glucophage tablets (metformin hydrochloride in 850mg strengths)
Dosing schedule: > 1.700mg/day for 6 month
Primary Outcome Measure Information:
Title
Change from Baseline of Patient self-reported subjective compliance as assessed by Haynes-Sackett test at Month 6
Time Frame
Month 6
Secondary Outcome Measure Information:
Title
Objective compliance to treatment
Description
Objective compliance to treatment is assessed by the accountability of medication returned. Patient is assessed as compliant with an adherence of over 80%.
Time Frame
Month 3 and month 6
Title
Evaluation of treatment satisfaction and preferences with the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time Frame
Baseline, month 3 and month 6
Title
Rate of reported adverse events
Time Frame
Month 3 and month 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diabetes mellitus type 2 diagnosed (Baseline Glycemia > 7,0 mmol/L (126 mg/dL) or overload Glycemia > 11,0 mmol/L (198 mg/dL)
On treatment with metformin tablets
Patients with at least 2 treated co-morbidities
Established dose of Metformin > 1.700 mg/day
Age > 18 years old
Given informed consent
Exclusion Criteria:
Patients not able to take medication orally
According to Summary of Product Characteristics (SmPC)
Participating in another clinical trial 30 days prior to randomization
Any other illness or medical or psychiatric condition, severe and uncontrolled that could interfere in the patient's participation or in the assessment of the study results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Responsible
Organizational Affiliation
Merck, S.L., Spain
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
We'll reach out to this number within 24 hrs